
Publication: DLBCL arising from indolent lymphomas: How are they different?
Publié dans: Seminars in Hematology, 2023, 60 (5), pp.277-284. ⟨10.1053/j.seminhematol.2023.11.002⟩
Auteurs: Erin Parry, Sandrine Roulland, Jessica Okosun
Résumé
Transformation to diffuse large B-cell lymphoma (DLBCL) is a recognized, but unpredictable, clinical inflection point in the natural history of indolent lymphomas. Large retrospective studies highlight a wide variability in the incidence of transformation across the indolent lymphomas and the adverse outcomes associated with transformed lymphomas. Opportunities to dissect the biology of transformed indolent lymphomas have arisen with evolving technologies and unique tissue collections enabling a growing appreciation, particularly, of their genetic basis, how they relate to the preceding indolent lymphomas and the comparative biology with de novo DLBCL. This review summarizes our current understanding of both the clinical and biological aspects of transformed lymphomas and the outstanding questions that remain.
Lien vers HAL – hal-04534451
Lien vers le DOI – 10.1053/j.seminhematol.2023.11.002